title: Prostaglandin E2, a postulated astrocyte-derived neurovascular coupling agent, constricts rather than dilates parenchymal arterioles.
abstract: It has been proposed that prostaglandin E(2) (PGE(2)) is released from astrocytic endfeet to dilate parenchymal arterioles through activation of prostanoid (EP(4)) receptors during neurovascular coupling. However, the direct effects of PGE(2) on isolated parenchymal arterioles have not been tested. Here, we examined the effects of PGE(2) on the diameter of isolated pressurized parenchymal arterioles from rat and mouse brain. Contrary to the prevailing assumption, we found that PGE(2) (0.1, 1, and 5 μmol/L) constricted rather than dilated parenchymal arterioles. Vasoconstriction to PGE(2) was prevented by inhibitors of EP(1) receptors. These results strongly argue against a direct role of PGE(2) on arterioles during neurovascular coupling.
authors: Department of Pharmacology, College of Medicine, University of Vermont, Burlington, VT 05405-0068, USA.
authors: Fabrice
authors: F
authors: Dabertrand
authors: Rachael M
authors: RM
authors: Hannah
authors: Jessica M
authors: JM
authors: Pearson
authors: David C
authors: DC
authors: Hill-Eubanks
authors: Joseph E
authors: JE
authors: Brayden
authors: Mark T
authors: MT
authors: Nelson
mesh_terms: D000818:Animals; D001160:Arterioles / Q000378:metabolism; D001253:Astrocytes / Q000378:metabolism*; D001921:Brain / Q000098:blood supply* / Q000378:metabolism; D002560:Cerebrovascular Circulation / Q000502:physiology*; D015232:Dinoprostone / Q000378:metabolism*; D008297:Male; D051379:Mice; D051381:Rats; D017207:Rats, Sprague-Dawley; D058306:Receptors, Prostaglandin E, EP1 Subtype / Q000378:metabolism; D014661:Vasoconstriction / Q000502:physiology*
chemical_list: D058306:Receptors, Prostaglandin E, EP1 Subtype; D015232:Dinoprostone
references: Circ Res. 1989 Jan;64(1):136-44
references: 2909297
references: PLoS One. 2011 Mar 04;6(3):e17360
references: 21394197
references: Br J Pharmacol. 2001 Nov;134(6):1296-302
references: 11704650
references: Nat Neurosci. 2006 Feb;9(2):260-7
references: 16388306
references: Br J Pharmacol. 1994 May;112(1):59-64
references: 8032662
references: Proc Natl Acad Sci U S A. 2012 May 22;109(21):E1387-95
references: 22547803
references: Proc Natl Acad Sci U S A. 2011 Sep 20;108(38):16104-9
references: 21896757
references: J Neurosci. 2011 Jul 6;31(27):9836-47
references: 21734275
references: Am J Physiol. 1991 Feb;260(2 Pt 2):H420-5
references: 1996685
references: Am J Physiol Regul Integr Comp Physiol. 2001 Nov;281(5):R1343-60
references: 11641101
references: Am J Physiol. 1979 Sep;237(3):H381-5
references: 382872
references: Proc Natl Acad Sci U S A. 2010 Dec 21;107(51):22290-5
references: 21135230
references: Pharmacol Ther. 1982;18(3):313-31
references: 6820155
references: Eur J Pharmacol. 1977 Jun 15;43(4):343-51
references: 407085
references: Nature. 2010 Nov 11;468(7321):232-43
references: 21068832
references: Circ Res. 2001 Mar 30;88(6):600-8
references: 11282894
references: J Pharmacol Exp Ther. 1985 Jun;233(3):628-35
references: 4009485
references: Nat Neurosci. 2006 Nov;9(11):1397-1403
references: 17013381
references: Biochim Biophys Acta. 2000 Jan 17;1483(2):285-93
references: 10634944
references: Prostaglandins Other Lipid Mediat. 2010 Apr;91(3-4):104-12
references: 19808012
references: Circ Res. 2012 Jan 20;110(2):285-94
references: 22095728
references: Proc Natl Acad Sci U S A. 2010 Feb 23;107(8):3811-6
references: 20133576
references: Nat Neurosci. 2003 Jan;6(1):43-50
references: 12469126
references: J Neurosci. 2000 Jan 15;20(2):763-70
references: 10632605
references: Nat Neurosci. 2007 Nov;10(11):1369-76
references: 17965657
references: Stroke. 1975 Jan-Feb;6(1):52-7
references: 1111183
references: J Neurosci. 2005 Oct 26;25(43):9858-70
references: 16251433